These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14610920)

  • 1. Emerging drugs for non-small cell lung cancer.
    Cappuzzo F; Bartolini S; Crinò L
    Expert Opin Emerg Drugs; 2003 May; 8(1):179-92. PubMed ID: 14610920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2002 Mar; 3 Suppl 1():S30-8. PubMed ID: 14720353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in non-small-cell lung cancer.
    Herbst RS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epidermal growth factor receptor in lung cancer.
    Baselga J; Albanell J
    Curr Oncol Rep; 2002 Jul; 4(4):317-24. PubMed ID: 12044241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecularly targeted therapy for gastrointestinal cancer.
    Wiedmann MW; Caca K
    Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for non-small cell lung cancer.
    Papaetis GS; Roussos C; Syrigos KN
    Curr Pharm Des; 2007; 13(27):2810-31. PubMed ID: 17897025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    Kelly K; Huang C
    J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New molecular targeted therapies integrated with radiation therapy in lung cancer.
    Provencio M; Sánchez A; Garrido P; Valcárcel F
    Clin Lung Cancer; 2010 Mar; 11(2):91-7. PubMed ID: 20199974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for advanced non-small cell lung cancer.
    Starakis I; Nikolakopoulos A; Mazokopakis EE
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
    Kim DW; Choy H
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
    Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
    Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.